Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.

NCT06208072 is registered in ClinicalTrials.gov with Hippocration General Hospital as lead sponsor.

NCT NCT06208072
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT06208072 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
The Predictive Role of Urinary Proteomics in Blood Pressure Response of Obese Hypertensive Treated With Irbesartan or Eplerenone.
Lead sponsor
Hippocration General Hospital
Phase
Not applicable
Overall status
Unknown status
Start date
September 1, 2023
Completion date
February 1, 2025
Enrollment
50 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

obesity, primary hypertension